Please login to the form below

Not currently logged in
Email:
Password:

supply chain

This page shows the latest supply chain news and features for those working in and with pharma, biotech and healthcare.

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

Meanwhile, Bayer is contributing its expertise and established infrastructure in clinical operations, regulatory affairs, pharmacovigilance, medical information and supply chain performance to support the development, supply and key territory

Latest news

More from news
Approximately 3 fully matching, plus 213 partially matching documents found.

Latest Intelligence

  • Strategy experts: the real thing Strategy experts: the real thing

    Experts can exist in any part of our industry’s value chain, from discovery to commercialisation and all points in between. ... The supply chain specialist who advances logistical practice shows another, and the senior marketer who elevates the level

  • A new era for UK-Japanese scientific research relations A new era for UK-Japanese scientific research relations

    It relies heavily on those markets to meet its demand for pharmaceutical goods, while providing opportunities for pharmaceutical supply chain services, such as contract research organisations (CROs) like Richmond Pharmacology, to

  • Achieving an agile supply chain Achieving an agile supply chain

    Supply chain resilience has never been more important. Supply chain resilience has never been more important. ... Similarly, lead times across a global supply chain are very hard to predict, demanding continuous modification to production schedules.

  • Rebranding in an evolving world Rebranding in an evolving world

    Our lean operating model combined with regulatory, quality and supply-chain capabilities across almost 100 countries means we are also able to acquire and integrate new products and companies quickly and ... The solidification of our long-lived

  • How can virtual pharma companies de-risk new product launches? How can virtual pharma companies de-risk new product launches?

    through to marketing, supply chain design, sales, distribution and other post- launch activities. ... entire supply chain with all the obligations that are pertinent to these activities.

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....